Introduction. Currently, COVID-19 treatment includes several options, including the use of convalescent plasma. In this context, the presence of anti-SARS-CoV-2 in blood donors after the clinical recovery of COVID-19 depending on the place of residence, age and the clinical manifestation of the disease is of scientific-practical interest. The aim of the study: is to investigate how the use of blood plasma from people who have been cured of COVID-19 and given to critically ill patients can give them an immune boost. Material and methods. A total of 119 donors were examined from patients - 18-60 years old males with a history of COVID-19 disease, PCR confirmed case, cured with negative result for COVID-19 in a PCR test and at least 14 days after clinical recovery. The presence / absence of anti-SARS-CoV-2 was assessed by enzyme-linked immunosorbent assay. Conclusion. The study shows that male blood donors aged 18-60 years, with a confirmed history of disease, later cured, positive for the presence of anti-SARS-CoV-2 IgG can serve as a source of fresh plasma used for the treatment of COVID patients. -19, especially with severe clinical manifestations of the disease., References: 1. Joyner J. M., Senefeld W. J., Klassen S.A et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv 2020.08.12.20169359; doi: https://doi.org/10.1101/2020.08.12.20169359. https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1 2. Sean T. H. Liu et al. Convalescent plasma treatment of severe COVID-19: A matched con-trol study. medRxiv 2020.05.20.20102236; doi: https://doi.org/10.1101/2020.05.20.20102236 3. Salazar, Eric, et al. "Treatment of Coronavirus Disease 2019 Patients With Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality." The American Journal of Pathology, vol. 190, no. 11, 2020, pp. 2290-2303. 4. Gharbharan, A. et al. Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv (2020). 5. Gilead Sciences. Gilead presents additional data on investigational antiviral remdesivir for the treatment of COVID-19 [Internet]. [cited 2020 october 19]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19. 6. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report [published online ahead of print, 2020 Jul 17]. N Engl J Med. 2020;NEJMoa2021436. doi:10.1056/NEJMoa2021436 7. Baum A, Ajithdoss D, Copin R, et. al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020 Oct 9:eabe2402. doi: 10.1126/science.abe2402. Epub ahead of print. PMID: 33037066. 8. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study [published online ahead of print, 2020 Mar 18]. Engineering (Beijing). 2020;10.1016/j.eng.2020.03.007. doi:10.1016/j.eng.2020.03.007 9. Caly, Leon, et al. "The FDA-approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro." Antiviral Research, vol. 178, 2020, p. 104787. 10. Reuters Staff. Merck plans large trials of antiviral COVID-19 drug in September. [Internet]. [cited 2020 october 19]. Available from: https://in.reuters.com/article/merck-co-results-antiviral/merck-plans-large-trials-of-antiviral-covid-19-drug-in-september-idINFWN2F212I 11. U.S. Food and Drug Administration. CytoSorb ® 300 mL Device Approved by FDA for Emergency Treatment of COVID-19 (2020). [Internet]. [cited 2020 october 19]. Available from: https://www.aferetica.com/en/fda-usa-approved-for-emergency-cytosorb-300-ml-device-treatment-of-covid-19/ 12. Stockmann H, Keller T, Büttner S, et al. CytoResc - "CytoSorb" Rescue for critically ill pa-tients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a ran-domized controlled trial. Trials. 2020;21(1):577. Published 2020 Jun 26. doi:10.1186/s13063-020-04501-0 13. Weill Medical College of Cornell University. Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) (IMPACT). [Internet]. [cited 2020 october 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT04406389 14. Zhang B, Zhou X, Zhu C, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci. 2020;7:157. Published 2020 Jul 3. doi:10.3389/fmolb.2020.00157 15. Furtuna N., Druc A., Sajin O. et al. Epidemiology of the initial period of novel coronavirus (COVID-19) pandemic in the Republic of Moldova. Journal One Health & Risk management, Vol. 2, Issue 2, 2020, p.5-16. https://doi.org/10.38045/ohrm.2020.1.11 16. WHO. Screening Donated Blood for Transfusion-Transmissible Infections: Recommenda-tions. Geneva: World Health Organization; 2009. ISBN-13: 978-92-4-154788-8 17. Consensus statement on screening blood donations for infectious agents through blood transfusion. Geneva: World Health Organization Global Programme on AIDS/League of Red Cross and Red Crescent Societies; 1991. WHO/LBS/91.1. 18. Dodd RY. Current risk for transfusion-transmitted infections. Current Opinion in Hematol-ogy. 2007;14(6):671–676. Review 19. Order of the Ministry of Health, Labor and Social Protection of the Republic of Moldova n 394 of 13.04.2020 "On the strengthening of measures for blood transfusion assistance to patients with COVID-19". 20. Long, Q., Tang, X., Shi, Q. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26, 1200–1204 (2020). https://doi.org/10.1038/s41591-020-0965-6 21. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti–SARS-CoV-2 an-tibodies in persons with mild Covid-19. N Engl J Med. 2020;doi: 10.1056/NEJMc2025179 22. CIDRP. Center for infectious disease research and policy. Study: COVID-19 antibodies decay quickly after mild illness. [Internet]. [cited 2020 october 20]. Available from: https://www.cidrap.umn.edu/news-perspective/2020/07/study-covid-19-antibodies-decay-quickly-after-mild-illness 23. Lilly investors. Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans. [Internet]. [cited 2020 october 20]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-begins-worlds-first-study-potential-covid-19-antibody 24. Zhongji Meng, Tongyu Wang, Chen Li, Xinhe Chen, Longti Li, Xueqin Qin, Hai Li, Jie Luo. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv 2020.04.11.20061473; doi: https://doi.org/10.1101/2020.04.11.20061473 25. Beigel, John H et al. "Remdesivir for the Treatment of Covid-19 - Final Report." The New England journal of medicine, NEJMoa2007764. 8 Oct. 2020, doi:10.1056/NEJMoa2007764 26. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023